Organon & Co. (OGN)
Organon & Co. (OGN) is a global healthcare company specializing in the development and commercialization of pharmaceutical and biosimilar products. It focuses on women’s health, reproductive rights, and other therapeutic areas, aiming to improve health outcomes through innovative medicines. The company was spun off from Merck & Co. in 2021 to concentrate on its dedicated portfolio of women’s health, biosimilars, and other biopharmaceuticals.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 11, 2025 | $0.02 | 2025-08-15 | 2025-08-15 |
| June 12, 2025 | $0.02 | 2025-05-12 | 2025-05-12 |
| March 13, 2025 | $0.28 | 2025-02-24 | 2025-02-24 |
| December 12, 2024 | $0.28 | 2024-11-12 | 2024-11-12 |
| September 12, 2024 | $0.28 | 2024-08-16 | 2024-08-16 |
Dividends Summary
- Organon & Co. has issued 17 dividend payments over the past 4 years
- The most recent dividend was paid 9 days ago, on September 11, 2025
- The highest dividend payed out to investors during this period was $0.28 per share
- The average dividend paid during this period was $0.25 per share.
Company News
Women's Health Collective Canada launched Vital Talks, a national online seminar series focusing on women's health, starting with a menopause care event supported by multiple healthcare and research partners.
Daré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.
Organon has completed the acquisition of Dermavant Sciences, a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology, including the FDA-approved VTAMA® (tapinarof) cream for the treatment of plaque psoriasis.
Organon reported Q2 2024 revenue of $1.61 billion, down 0.1% year-over-year, and EPS of $1.12 compared to $1.31 a year ago. The company's performance was mixed compared to analyst estimates, with revenue missing expectations but EPS beating estimates.